Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- San Diego, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 6 people enrolled
- Started
- 20 Nov 2023
- Ended
- 31 Mar 2025
- Type of study
- Interventional
- Treatments tested
- leucoselect phytosome
- Record updated
- 17 February 2026
- Why it stopped
- Early termination by sponsor due to substantial delays with subjects recruitment
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Initial screening:
- Lesions suspicious for lung cancer
- Competent to provide consent
- CBC within normal limits (WNL)
- liver function test WNL
- Normal Creatinine clearance as measured by the Cockcroft-Gault equation
- ECOG Performance status: 0-1
- Enrollment for treatment with LP:
- Histologically proven and surgically resectable clinical I and II stage NSCLC
Who cannot take part
- Other concurrent malignancy, excluding non-melanoma type skin cancer
- Have had a solid organ or bone marrow transplant
- Systemic corticoid steroid therapy of > 10 mg prednisone equivalent daily
- Concurrent use of Grapes or related products
- Pts receiving medications known to be modulators of cytochrome P450 3A4 if alternative medication cannot be provided
- Currently taking other investigational agents
- Pts with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow up schedule
- Inability to provide informed consent (e.g. cognitive impairment, severe psychiatric disorders)
- Hypersensitivity to grapes or related products
- Advance respiratory disease (Post resection FEV1 < 0.8 liters, resting hypoxemia, to ensure pts have adequate reserve to undergo diagnostic procedures and surgical resection)
- Unstable angina
- Coagulopathy (PT-INR > 1.2, PTT > 40 seconds) or history of bleeding/clotting problems
- Pregnancy
- Breast feeding
- Unwilling to refrain from drinking more than 1 glass of wine a day
Where in United States
- VA San Diego Healthcare System, San Diego, CASan Diego, United States
About the trial
What the trial wants to find out
Lung cancer is the leading cause of cancer death in the country, surpassing deaths caused by colorectal, prostate and breast cancers combined. Veterans are at higher risk of lung cancer due to the higher rate of smoking and environmental toxin exposures. The lack of effective therapy for lung cancer provides the impetus to search for alternative, safe, and effective treatment agents to improve treatment strategy against lung cancer, enhance the probability of a cure and reduce recurrence. Based on encouraging preclinical and clinical findings from an early phase I lung cancer prevention study, using a special formulation of a standardized grape seed extract with enhanced absorption called leucoselect phytosome (LP), the purpose of this new CSR\&D Merit Review project is to evaluate the potential usefulness of LP for pre-surgical treatment of early stage lung cancer patients in a phase IIa clinical trial. Findings from this study may set the stage for larger, confirmatory trials in the near future.
The group in the trial
- InterventionTreatment being tested
All qualified participants meeting entry criteria that are enrolled will receive 2-3 weeks of oral LP treatment.
Treatment: leucoselect phytosome
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 February 2026